The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Peptide therapeutics from venom: Current status and potential
Open accessAbstract
Peptides are recognized as being highly selective, potent and relatively safe as potential therapeutics. Peptides isolated from the venom of different animals satisfy most of these criteria with the possible exception of safety, but when isolated as single compounds and used at appropriate concentrations, venom-derived peptides can become useful drugs. Although the number of venom-derived peptides that have successfully progressed to the clinic is currently limited, the prospects for venom-derived peptides look very optimistic. As proteomic and transcriptomic approaches continue to identify new sequences, the potential of venom-derived peptides to find applications as therapeutics, cosmetics and insecticides grows accordingly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OERKE, E.-C. (2006) · The Journal of Agricultural Science · doi:10.1017/s0021859605005708 · Cited by 5,283
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Insect resistance to Bt crops: lessons from the first billion acres
Tabashnik, B. E., Brévault, T., & Carrière, Y. (2013) · Nature Biotechnology · doi:10.1038/nbt.2597 · Cited by 1,086
McCormack, K., Santos, S., Chapman, M. L., Krafte, D. S., Marron, B. E., West, C. W., Krambis, M. J., Antonio, B. M., Zellmer, S. G., Printzenhoff, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220844110 · Cited by 244
Tarcha, E. J., Olsen, C. M., Probst, P., Peckham, D., Muñoz-Elías, E. J., Kruger, J. G., & Iadonato, S. P. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180762 · Cited by 167
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Furman, B. L. (2012) · Toxicon · doi:10.1016/j.toxicon.2010.12.016 · Cited by 166
Tarcha, E. J., Chi, V., Muñoz-Elías, E. J., Bailey, D., Londono, L. M., Upadhyay, S. K., Norton, K., Banks, A., Tjong, I., Nguyen, H., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191890 · Cited by 117
Self-citation
Cited by
An Overview of Drug Discovery and Development
Berdigaliyev, N., & Aljofan, M. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0307 · Cited by 396
Bordon, K. D. C. F., Cologna, C. T., Fornari-Baldo, E. C., Pinheiro-Júnior, E. L., Cerni, F. A., Amorim, F. G., Anjolette, F. A. P., Cordeiro, F. A., Wiezel, G. A., Cardoso, I. A., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01132 · Cited by 303
Schendel, V., Rash, L. D., Jenner, R. A., & Undheim, E. A. B. (2019) · Toxins · doi:10.3390/toxins11110666 · Cited by 285
Anti-fungal properties and mechanisms of melittin
Memariani, H., & Memariani, M. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10701-0 · Cited by 58
Immunological Responses to Envenomation
Ryan, R. Y. M., Seymour, J., Loukas, A., Lopez, J. A., Ikonomopoulou, M. P., & Miles, J. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661082 · Cited by 49
Metadata
- Authors
- Pennington, M. W., Czerwinski, A., & Norton, R. S.
- Venue
- Bioorganic & Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 26
- Issue
- 10
- Pages
- 2738-2758
- ISSN
- 0968-0896 (ISSN-L)
- OpenAlex
- W2757640349
- Cited by
- 278
- References
- 8
- FWCI
- 18.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peptide therapeutics from venom: Current status and potential. https://app.cochat.ai/papers/10.1016/j.bmc.2017.09.029
- The paper
- Pennington, M. W., Czerwinski, A., & Norton, R. S. (2018). Peptide therapeutics from venom: Current status and potential. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2017.09.029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
